Dr. Reddy's Laboratories reported Q1 FY27 consolidated revenue of ₹8,071 crore (down 6% YoY) and net profit of ₹443 crore (down ~69% YoY), with EBITDA margin collapsing to 12.5% from ~26.7% a year ago, as North America revenue fell 35% on sharply lower lenalidomide sales and a ₹240 crore semaglutide API provision hit. The stock fell ~9% to a 52-week low.
Revenue fell 6%. Profit fell 69%. Those two numbers tell completely different stories, and a CFO reads the gap between them — not the headline.
Here's what a CFO would go straight to: gross margin. <Dr. Reddy's gross margin fell from 56.9% to 46.5% in a single quarter.> That's a 10-percentage-point collapse. When a pharma company loses a high-margin blockbuster generic — in this case, lenalidomide (a cancer drug that briefly gave DRL a near-monopoly window in the US) — the revenue line barely flinches. But the profit line craters, because that one product was carrying a disproportionate share of the margin.
This is operating leverage working in reverse. Fixed costs — R&D, manufacturing, regulatory, people — don't go away when a single product's exclusivity ends. So EBITDA margin more than halved: from ~27% to 12.5%. That's the number a CFO watches, because it shows whether the core business can cover its cost structure without the lucky drug.
A CFO would then ask: what replaces lenalidomide? The semaglutide (think: Ozempic generics) bet is visible — but a ₹240 crore provision on that API tells you the timeline slipped.
The lesson: revenue is what you sell. EBITDA is what you actually run. One blockbuster product can make those two numbers look like they belong to different companies.
📚 Learn the concept: EBITDA & EBIT
▶ Play the 90-second CFO game All daily posts